Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) FCF Margin (2023 - 2025)

Entrada Therapeutics (TRDA) has 3 years of FCF Margin data on record, last reported at 2559.2% in Q4 2025.

  • For Q4 2025, FCF Margin fell 247299.0% year-over-year to 2559.2%; the TTM value through Dec 2025 reached 509.63%, down 48842.0%, while the annual FY2025 figure was 509.63%, 48842.0% down from the prior year.
  • FCF Margin reached 2559.2% in Q4 2025 per TRDA's latest filing, down from 1754.21% in the prior quarter.
  • Across five years, FCF Margin topped out at 798.62% in Q1 2023 and bottomed at 2559.2% in Q4 2025.
  • Average FCF Margin over 3 years is 469.85%, with a median of 106.73% recorded in 2024.
  • Peak YoY movement for FCF Margin: surged 24246bps in 2024, then crashed -247299bps in 2025.
  • A 3-year view of FCF Margin shows it stood at 1.0% in 2023, then plummeted by -8751bps to 86.21% in 2024, then crashed by -2869bps to 2559.2% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 2559.2% in Q4 2025, 1754.21% in Q3 2025, and 1453.59% in Q2 2025.